Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

21.0%

13 terminated/withdrawn out of 62 trials

Success Rate

78.0%

-8.5% vs industry average

Late-Stage Pipeline

53%

33 trials in Phase 3/4

Results Transparency

61%

28 of 46 completed trials have results

Key Signals

2 recruiting28 with results13 terminated

Enrollment Performance

Analytics

Phase 4

19(41.3%)

Phase 3

14(30.4%)

Phase 2

5(10.9%)

N/A

4(8.7%)

Phase 1

2(4.3%)

Early Phase 1

2(4.3%)

46Total

Phase 4(19)

Phase 3(14)

Phase 2(5)

N/A(4)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (62)

Showing 20 of 62 trials

NCT04973007Phase 4Terminated

Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases

Role: collaborator

NCT03107520Early Phase 1Recruiting

Intraoperative Contrast-Enhanced Ultrasound Evaluation of Blood Flow at the Time of Surgical Hip Reduction for DDH

Role: collaborator

NCT06400004Phase 3Recruiting

Lumason® Infusion vs. Bolus Administrations

Role: lead

NCT03779906Phase 4Terminated

Thyroid Function of Pediatric Subjects Following Isovue® Administration

Role: lead

NCT03318380Not ApplicableCompleted

Contrast-Enhanced Ultrasound Imaging in Diagnosing Liver Cancer in Patients With Cirrhosis

Role: collaborator

NCT03549520Phase 3Completed

CEUS Evaluation of Hypoxic Ischemic Injury

Role: collaborator

NCT03549507Phase 3Terminated

CEUS Evaluation of Bowel Perfusion in Necrotizing Enterocolitis

Role: collaborator

NCT03493464Phase 2Terminated

BR55 in Characterization of Ovarian Lesions

Role: lead

NCT04248153Phase 2Terminated

Optimal Timing of BR55 CEUS of the Ovaries

Role: lead

NCT03486327Phase 2Terminated

Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions

Role: lead

NCT01390194Completed

Rapid 10-Minute Liver MRI Protocol in Patients With Suspected Hepatocellular Carcinoma

Role: collaborator

NCT00415805Phase 3Completed

Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent

Role: lead

NCT01253213Early Phase 1Completed

BR55 in Prostate Cancer: an Exploratory Clinical Trial

Role: lead

NCT04453059Completed

Study With Oral Isovue in Abdominopelvic CT

Role: lead

NCT02552238Phase 3Completed

Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142

Role: lead

NCT02522481Phase 3Completed

Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141

Role: lead

NCT02142608Phase 1Completed

A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer

Role: lead

NCT00395863Phase 4Completed

Multihance at 3 Tesla (3T) in Brain Tumors

Role: lead

NCT01136876Phase 4Completed

Kidney Damage in Patients With Moderate Fall in eGFR

Role: lead

NCT03108378Completed

Evaluation of Gd Retention in Human Bone and Skin After MultiHance or ProHance Administration Compared With Control

Role: lead